Member Info for Soupdragon78

given that full year results are due that is likely to be the rns.

Stuck in the car all day driving up north, good to see continuation from yesterday

Unless they sneak them out tomorrow. Friday treat.

MM's just moved up on pretty much nothing.

The mm's love it, they can take shares off peoples hands down at 0.32p and then sell them to punters at 0.38p

Don’t know any names Jiving, plus I’ve never seen anything linking Kissei.

From Nov 2019, discussions not just in Asia but US as well.

“Funds from the Placing will allow Nuformix to drive progress in this programme and support Nuformix's position in the Group's on-going discussions with multiple potential development partners in Asia and the US.”

Jiving, what about Kissei and the multiple other parties they were previously in discussion with?

FX. It means there is no conflict of interest.

ERS isn’t a used car saleman convention. Abstracts are presented in a scientific forum.

We'll hear from him on 6 Sept Etot, when he presents NXP002.

Simon Cruwys seems to know what he's talking about after his time at AZ.

NXP004 is undertaking new studies to move toward formulation.
Hence its in a better position than it was at the start of the year.

When we get to 6p yes I’ll buy them for 5p

bloods always been consistent that its going down, just odd in that he's never wanted to sell.

The ERS info is an assumption. Looking at the ERS website it identifies that abstracts had to be submitted by mid December, but this was extended to February. The ERS then notifies companies mid/late June.
This would mean that the work within NFX likely involved Brindley for a submission in December, or she could have done the work then submitted by Riddell in January.

To me this means that the abstract will not contain anything relating to 'new' work being done from August, it is likely covering the in-vivo and in-vitro work that was successful in the second half of last year.

In the short term, as mentioned before, will be the Full Year Results. We know its not really about the numbers given the point in time they are at, but more about how they are setting out a strategy moving forward.

Also key for me is any identification of who will be at the ERS Conference. Their abstract submission was made back in January, so would have been done by Riddell and most likely written by Brindley. So in terms of who presents / promotes the work at the conference will be interesting. Will it be Gilbert, or would Gooding be presenting due to his prior knowledge / business development aspect? Or someone new?

The work on NXP002 then kicks off in August with announcements along the way throughout the autumn. There are a number of studies underway at the same time.
NXP004 is already moving forward towards formulation.
NXP001 (OXL001) will be in clinical trials during the second half of the year with milestone payments to NFX.

Goup, didn’t you tell us AR would be good holding the reigns.

Small cap pick has been in and out of this so many times, usually part of the pump and dumps around the 1p level.
Uses bot followers to try and spread his posts.

But agree the valuation is ridiculous considering Oxilio are valued at £51m and are reliant on one NFX cocrystal which is also of the least potential value.

Not sure where they get the £2m cash figure from. Thats way out, even Allenby said the high cash point would be 940k.

Would argue the opposite filter. They’d been on the bid trying to buy 1.6m shares and had to up their price to 0.37p

Lol. too true filter, I'm sure their bot followers will be pleased with the tip, especially as allthewinners posted something identical ten mins before aboout N4P